The European Parliament hosted its first symposium on pharmaceuticals on the theme of: Putting an end to Drug Counterfeiting," assembling European policy makers, regulators and specialists in counterfeiting and the drugs trade, at the Brussels, Belgium, EP building.
The event was welcomed by the branded drug manufacturers, which are concerned about the infiltration of the distribution chain by counterfeiters. However, representatives of Europe's legal parallel trade firms expressed "disappointment" at not being invited to the event, reinforcing their suspicions that drug majors are exploiting the security issue to justify anticompetitive pressure on distributors that exploit price differentials between European Union member states.
The European Association of Euro-Pharmaceutical Companies said it "strongly welcomes" the symposium, adding that "it is crucial to bring together industry stakeholders, regulators and policymakers in an effort to explore ways of reducing the risk of counterfeits reaching the European patient."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze